Editorial review: How early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?

Current Opinion in Rheumatology

Volumn 22, Issue 4, 2010, Pages 388-392

  Haibel, Hildrun ^a   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ankylosing spondylitis; Axial nonradiographic spondyloarthritis; Early therapy; Tumor necrosis factor blockers

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; DELAYED DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; EARLY INTERVENTION; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOTHERAPY; PRIORITY JOURNAL; REMISSION; REVIEW; SPONDYLOARTHROPATHY; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953477904     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32833aaf93     Document Type: Review

References (45)

1. Braun J, Bollow M, Remlinger G, et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998; 41:58-67.
2. Johnsen K, Gran JT, Dale K, Husby G. The prevalence of ankylosing spondylitis among Norwegian Samis (Lapps). J Rheumatol 1992; 19:1591-1594.
3. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-1390.
4. Feldtkeller E, Khan MA, van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 2003; 23:61-66.
5. Landewe R, Dougados M, Mielants H, et al. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 2009; 68:863-867.
6. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27:361-368.
7. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005; 52:1000-1008.
8. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009; 60:717-727.
9. Braun J, Bollow M, Eggens U, et al. Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 1994; 37:1039-1045.
10. Bennett AN, McGonagle D, O'Connor P, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008; 58:3413-3418.
11. Oostveen J, Prevo R, den Boer J, van de Laar M. Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography: a prospective, longitudinal study. J Rheumatol 1999; 26:1953-1958.
12. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009; 68:1520-1527.
13. Brandt HC, Spiller I, Song IH, et al. Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis. Ann Rheum Dis 2007; 66:1479-1484.
14. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68:777-783.
15. van der Heijde D, Sieper J, Maksymowych W, et al. Update of the ASAS recommendations on the use of TNF-blockers in ankylosing spondylitis. arthritis and Rheumatism 2009; 60 (Suppl 10):S670.
16. Haibel H, Brandt HC, Song IH, et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16 weeks open-label trial. Ann Rheum Dis 2007; 66:419-421.
17. Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64:124-126. (Pubitemid 40075288)
18. Dougados M, van der Linden S, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995; 38:618-627.
19. Amor B, Dougados M, Listrat V, et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995; 62:10-15.
20. Wanders A, van der Heijde D, Landewe R, et al. Inhibition of radiographic progression in ankylosing spondylitis (AS) by continuous use of NSAIDs. Arthritis Rheum 2003; 48 (Suppl):S233.
21. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187-1193.
22. Van Der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52:582-591.
23. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48:3230-3236.
24. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48:1667-1675.
25. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:2136-2146.
26. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-3412.
27. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003; 48:1126-1136.
28. Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 2005; 52:1216-1223.
29. Lambert RG, Salonen D, Rahman P, et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007; 56:4005-4014.
30. Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to antitumour necrosis factor treatment in ankylosing spon dylitis. Ann Rheum Dis 2008; 67:1276-1281.
31. Giardina A, Ciccia F, Principato A, et al. Patients with short duration (5 years) ankylosing spondylitis respond rapidly and maintain partial remission over a two years period when treated with TNF-blocking agents. Ann Rheum Dis 2008; 67624 (Suppl II):624.
32. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiograph ically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58:1981-1991.
33. Barkham N, Keen HI, Coates LC, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009; 60:946-954.
34. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 7:R439-R444.
35. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005; 44:342-348.
36. AmtenbrinkA, Haibel H, Rudwaleit M, et al. Adalimumab successfully re-treats and maintains long-term efficacy in axial spondyloarthritis (SpA) patients without radiographic sacroiliitis who relapse following adalimumab withdrawal. Arthritis and Rheumatism 2008; 58 (Suppl 9):S304.
37. Barkham N, Keen HI, Coates LC, et al. Clinical response and time to active disease following infliximab therapy in patients with HLA-B27 positive very early ankylosing spondylitis. Ann Rheum Dis 2009; 68 (Suppl 3):72.
38. van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008; 58:3063-3070.
39. Van der Heijde D, Landewe R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008; 58:1324-1331.
40. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11:R127.
41. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008; 58:649-656.
42. Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008; 10:R104.
43. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009; 60:93-102.
44. Braun J, Landewe R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54:1646-1652.
45. Haibel H, Baraliakos X, Rudwaleit M, et al. Adalimumab reduces inflammation in the sacroiliac joints of patients with active spondyloarthritis without radiographic sacroiliitis: results of a placebo-controlled, double blind clinical trial trough 52 weeks. Ann Rheum Dis 2009; 68 (Suppl 3):628.